|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12Q 1/6886 | |
| A61K 31/454 | |||
| A61K 31/506 | |||
| A61K 31/519 | |||
| G01N 33/50 | |||
| G01N 33/574 |
| (11) | Number of the document | 3309263 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17198700.1 |
| Date of filing the European patent application | 2013-06-26 | |
| (97) | Date of publication of the European application | 2018-04-18 |
| (45) | Date of publication and mention of the grant of the patent | 2019-12-25 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201261669534 P | 2012-07-09 | US |
| (72) |
CAPONIGRO, Giordano, US
DELACH, Scott, US
GARRAWAY, Levi, US
JAGANI, Zainab, US
KIM, Sunkyu, US
KRYUKOV, Gregory, US
|
| (73) |
Dana-Farber Cancer Institute, Inc.,
450 Brookline Avenue, Boston, MA 02215-5450,
US
Broad Institute, 44 Binney Street, Boston, Massachusetts 02115, US Novartis AG, Lichtstrasse 35, 4056 Basel, CH |
| (54) | BIOMARKERS ASSOCIATED WITH CDK INHIBITORS |
| BIOMARKERS ASSOCIATED WITH CDK INHIBITORS |